Ansell Limited

The Business

Ansell manufactures personal protective equipment (PPE), the gloves, suits, and body protection that workers in hospitals, factories, and laboratories are required to wear. The company operates two divisions of roughly equal size: Healthcare (55% of revenue), covering surgical gloves, exam gloves, and life sciences protection, and Industrial (45%), covering mechanical, chemical, and cleanroom applications. The July 2024 acquisition of Kimberly-Clark's PPE division (KBU) added cleanroom and body protection verticals, making Ansell the global leader in cleanroom PPE. Revenue is earned in US dollars across more than 100 countries, but the shares trade in Australian dollars on the ASX, creating a persistent currency translation layer for local investors.

Recent Performance

FY25 revenue jumped 23.7% to US$2.0 billion, though this was almost entirely the KBU acquisition rather than organic momentum (the prior year base of US$1.6 billion itself reflected post-pandemic destocking). EBIT margins expanded from 12.1% to 14.1%, driven by the company's cost restructuring programme (APIP), which delivered US$50 million in permanent savings through plant closures and headcount reductions. H1 FY26 continued the trend: revenue of US$1.03 billion with a 14.3% EBIT margin, and management guided full-year EPS of US137-149 cents.

Outlook

We forecast revenue growing at roughly 3% annually to US$2.2 billion by FY28, driven by modest organic growth across both divisions plus KBU synergies tracking to US$15 million. EBIT margins should peak near 14.8% in FY28 as APIP savings and KBU integration benefits fully flow through, before gradually fading toward 13.5% as cost inflation erodes the restructuring gains. EPS growth of 5-7% per annum through FY28 is achievable. The outlook is stable but unspectacular, which is the core tension: decent execution in a mature market that grows 4-5% per year, with Ansell historically capturing less than that organically.

Key Risks

Currency translation dominates: the AUD currently sits at the 67th percentile of its historical range and is trending higher, which means every meaningful move in the Australian dollar materially affects the share price for ASX investors, with no effective company-level hedge. Organic growth stagnation is the thesis risk, with a five-year organic CAGR of roughly zero; if post-KBU growth settles at 1% rather than 3%, the impact on intrinsic value is substantial. A dual CEO/CFO transition, with both executives under 12 months into their roles, adds execution uncertainty during a period of complex integration and system migration.

What to Watch

The thesis-defining event is Ansell's FY26 full-year results in August 2026, which will be the first set of guidance issued by new CEO Ahlström and will reveal whether organic growth is tracking above 2% or stalling below 1%.

• 12-18 months Industrial recovery (PMI above 50) — would lift the Industrial segment's 45% revenue contribution, but current PMI of 45 suggests this is at least two quarters away.
• FY27 KBU synergy realisation — management targets US$15 million with 30% probability of exceeding it.

Latest Developments

Ansell reported H1 FY26 results in February 2026, showing organic constant-currency sales growth of 2.1% and confirming full pass-through of approximately US$80 million in US tariff costs. The company maintained full-year EPS guidance of US137-149 cents. CEO Jussi Ahlström, who joined in October 2025 from Fiskars Group, has not yet issued independent strategic guidance.

Company Description

Ansell is a global manufacturer of protective gloves and body protection, headquartered in Melbourne but reporting in US dollars. The Healthcare division (55% of FY25 revenue) produces surgical gloves under the GAMMEX brand, examination gloves, and life sciences protection. The Industrial division (45%) covers mechanical protection (HyFlex brand), chemical protection (AlphaTec), and, since the KBU acquisition, cleanroom garments and body protection (Kimtech). Manufacturing spans 14 plants across Malaysia, Sri Lanka, Thailand, Vietnam, Portugal, Lithuania, Brazil, Mexico, and the United States. This geographic spread is not incidental: it means no single country accounts for more than 30% of US imports, a structural advantage in the current tariff environment.

Where the Growth Is

The KBU acquisition, completed in July 2024, is the primary growth engine. It added cleanroom and body protection verticals that now contribute roughly 30% of Industrial segment revenue. Ansell holds the number one global position in cleanroom PPE, a segment growing faster than the group average due to semiconductor and pharmaceutical cleanroom expansion. KBU synergies are tracking to US$15 million by FY27, with cross-selling through the AnsellGUARDIAN digital platform (which recommends PPE solutions by workplace hazard) adding further strategic option value. Beyond KBU, the India greenfield facility under construction adds low-cost manufacturing capacity for the domestic market.

Competitive Position

Three companies, Ansell, Honeywell, and MSA Safety, control the majority of the premium industrial PPE market outside commodity exam gloves. Ansell's competitive advantages are brand-driven rather than cost-driven. The HyFlex mechanical glove and GAMMEX surgical glove carry 200-400 basis points (2-4 percentage points) of pricing premium over unbranded alternatives because they are specified into workplace safety protocols. Once a safety manager approves a specific glove for a task, switching requires re-certification, creating meaningful switching costs in regulated environments. These advantages are real but narrow: they apply primarily to surgical, cleanroom, and mechanical segments, not to commodity exam gloves, which represent roughly half of Healthcare revenue and compete largely on price. The competitive position is stable and likely durable for five to seven years, supported by declining competitive intensity as Kimberly-Clark exited PPE (to Ansell) and Honeywell restructures its safety division.

Management & Capital Discipline

The outgoing management team under CEO Neil Salmon delivered on every major commitment. APIP restructuring produced US$50 million in permanent cost savings on schedule. The KBU acquisition was completed at 8.5 times EBIT, below the sector median of 9 times, and integration is running ahead of plan. A US$200 million buyback was executed at prices we estimate were reasonable relative to intrinsic value. The honest observation: all of this track record belongs to Salmon, who departed in late 2025. New CEO Jussi Ahlström, previously of Fiskars Group, has zero PPE industry experience and has not yet articulated his own strategy. The company's credibility is inherited, not demonstrated, under current leadership. Salmon remains in an advisory capacity, providing some continuity, but investors are essentially underwriting an untested executive team managing a complex integration, an ERP system rollout, and tariff repricing simultaneously.

Financial Position

The balance sheet is healthy. Net debt (total borrowings minus cash) sits at approximately US$483 million, or 1.3 times EBITDA (earnings before interest, tax, depreciation, and amortisation). The company has more than US$500 million in undrawn credit facilities. Interest coverage is comfortable at roughly seven times. Goodwill of US$1.34 billion represents 68% of total equity, which is the main balance sheet vulnerability: a 15% write-down would reduce book equity by approximately 10%. The company can comfortably weather a downturn and has capacity for bolt-on acquisitions, though we do not assume any in our base case.